Relation of fibroblast growth factor-23 and cardiovascular calcification in end-stage kidney disease patients on regular hemodialysis

Abstract EN

More than half of deaths in end-stage kidney disease (ESKD) patients are due to cardiovascular disease.

Elevated fibroblast growth factor 23 (FGF-23) was found to be associated with mortality in hemodialysis (HD) patients and correlates with peripheral calcification.

Aortic calcification is associated with coronary artery calcification.

Both aortic and peripheral vascular calcifications were associated with mortality in chronic kidney disease.

We aimed to investigate the relation between intact FGF-23 and cardiovascular calcification in patients with ESKD who were maintained on regular HD.

Sixty clinically stable ESKD patients on regular HD were enrolled into this cross-sectional study.

They were evaluated by basal abdominal X-ray.

They were divided into two groups: (Group A, n = 30), patients with abdominal aortic calcification who underwent multislice computerized tomography scan to measure coronary artery calcification score; and (Group B, n = 30), patients without abdominal aortic calcification.

All of them were evaluated by lipid profile and dialysis adequacy parameters.

Fifty percent of patients had vascular calcification.

We found a significant positive correlation between age and intact FGF-23; significant positive correlations between age, body mass index, duration of HD, and abdominal aortic calcification score.

FGF-23 of all patients was elevated and had significant positive correlation with aortic and coronary calcifications in addition to lipid profile, left ventricular mass index (LVMI), and inflammatory markers.

Plasma intact FGF-23 was elevated in nondiabetic